Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice the first effects of Wegovy within the first one to four weeks of starting treatment, though meaningful weight loss typically takes two to three months to become obvious on the scales. That timeline is shaped by how the dose escalation works, individual metabolism, and how closely lifestyle changes run alongside treatment. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it is clinically appropriate before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide acts on GLP-1 receptors in the brain and gut, reducing appetite and slowing how quickly the stomach empties. Those effects begin with the very first injection. What most people experience in week one or two is a shift in hunger cues: meals feel smaller, snacking urges drop, and the sense of fullness arrives sooner. Some people also notice mild nausea at this stage, which is a normal sign that the medicine is active in your system.
The reason weight loss itself takes longer is structural, not chemical. The 0.25mg starting dose is there to settle your digestive system before the dose climbs. The therapeutic doses where most of the clinical trial weight loss occurred (1.7mg and 2.4mg) are not reached until around week 17 of the standard schedule. Expecting dramatic results on the starter pen is setting the wrong clock.
You can read more about what shapes the overall timeline on our guide to how long Wegovy takes to work, which covers the full escalation schedule in detail. The NHS medicines page for semaglutide also describes how the medicine works and what to watch for in the early weeks.
In practice, most people report the scales shifting noticeably somewhere between weeks four and eight, even at lower doses. By the three-month mark, a clinically meaningful change in weight is usually visible for people who are responding well. The STEP 1 trial, which ran for 68 weeks, showed the rate of weight loss was steepest in the first six months, then slowed to a plateau as participants approached their new stable weight.
A few honest caveats. Some people are faster responders; others barely move until they hit the 1.0mg or 1.7mg dose. Factors like starting BMI, how much appetite reduction you're experiencing, and the quality of dietary changes running alongside the medicine all play a role. If you happen to start treatment the week before a holiday, or push your order to after payday, those first few weeks still count toward the titration clock, so there is no benefit in delaying once you have been approved.
Our timeline for when Wegovy begins to have an effect page breaks down the expectations at each dose step if you want a stage-by-stage view, and if you are curious about the early signals to look out for, our page on how long Wegovy takes to kick in goes into more detail on what those first responses feel like. For a broader picture of the evidence behind semaglutide for weight loss, NICE's technology appraisal TA875 summarises the trial data used to recommend its use in eligible adults.
Three months at maintenance dose, with consistent use and lifestyle changes in place, is a reasonable first checkpoint. If weight loss is less than 5% of starting body weight by that stage, NICE guidance suggests reviewing whether continuing treatment is appropriate — that clinical conversation sits with your prescriber, not a self-assessment.
Before concluding the medicine isn't working, it is worth checking a few practical things. Has the titration schedule been followed correctly? Skipping or delaying dose increases pushes the effective timeline back. Are injections being given consistently on the same day each week? Is the pen being stored in the fridge (2–8°C) and removed briefly before use? A prescriber can also check whether a different medicine, such as tirzepatide, might be a better fit; our weight-loss treatment overview covers what is currently available in the UK.
Concerns about side effects or slow progress are exactly the kind of thing our aftercare team handles. You can reach us through our support page seven days a week. If you're still weighing up whether semaglutide is right for you at all, the Wegovy pillar page gives a full picture of the medicine, its licence and what clinical assessment involves. For more detail on how it compares to the general semaglutide timeline, our page on how long it takes for semaglutide to kick in explores what the early weeks look like across the broader class of medicine, while our page on how long semaglutide takes to kick in offers a helpful comparison.
One thing our prescribers hear regularly: people are surprised the medicine is already working even when the scales haven't shifted much, because appetite changes are happening first. The weight follows. Speak to our prescribers if you want a clinical view of where you are in the process and whether your titration is on track — start with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.